POPULATION PHARMACOKINETIC METHODS TO OPTIMIZE ANTIBIOTIC EFFECTS

被引:14
作者
AMSDEN, GW
BALLOW, CH
SCHENTAG, JJ
机构
[1] Center for Clinical Pharmacy Research, School of Pharmacy, State University of New York at Buffalo
[2] The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, New York, 14209-1194
来源
DRUG INVESTIGATION | 1993年 / 5卷 / 05期
关键词
D O I
10.1007/BF03259590
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The concept of accelerating bacterial eradication and accomplishing a more rapid clinical cure by optimising dosing of antimicrobial agents is coming to fruition after many years of research. By integrating the pharmacokinetic parameters of an antibiotic with measures of microorganism susceptibility such as the minimum inhibitory concentration (MIC), it is possible to optimise both clinical and bacteriological cure. Recently, area under the inhibitory curve (AUIC) has been introduced as the 24-hour area under the curve (AUC) divided by the MIC. The AUIC has been shown to be an effective parameter to predict infectious outcome and it has the advantage that it can be easily calculated by estimating the patient's creatinine clearance and using population clearance of drugs vs creatinine clearance equations. In this review, total clearance vs creatinine clearance equations were derived for 53 antimicrobials, using pharmacokinetic data extracted from the literature. These equations were then validated by calculating half-life and AUC (for specific doses) and comparing the results to published values and ranges. In the validation phases the percentage error for each antibiotic equation was variable, ranging from 0.5 to 61% when estimating half-life, and 0.35 to 51% when estimating AUC. When a subset of antimicrobials was validated against values derived from studies of AUC vs decreasing creatinine clearance, the majority of percentage errors were within 0.35 to 56%, with only a minimal number of outliers over the studied ranges of renal function (0-129 ml/min/70kg). Possible explanations for these outliers include multiple routes of elimination and research based on populations different to those used to derive the original equation. Percentage errors were within acceptable ranges, when considering that most antimicrobials have a large therapeutic/toxic ratio. By targeting an AUIC value of 350, well above the theoretical threshold therapeutic value of 125, doses associated with an accelerated bacterial eradication rate are possible without substantially overdosing the patient. This remains true even if the calculated values from these equations are greater than a 50% overestimation.
引用
收藏
页码:256 / 268
页数:13
相关论文
共 54 条
  • [31] Matzke G.R., McGory R.W., Halstenson C.E., Keane W.F., Pharmacokinetics of vancomycin in patients with various degrees of renal function, Antimicrobial Agents and Chemotherapy, 25, pp. 433-437, (1984)
  • [32] Matzke G.R., Millikin S.P., Kovarik J.M., Variability in pharmacokinetic values for gentamicin, tobramycin, and netilmicin in patients with renal insufficiency, Clinical Pharmacy, 8, pp. 800-806, (1989)
  • [33] Meyers B.R., Srulevitch E.S., Jacobson J., Hirschman S.Z., Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers, Antimicrobial Agents and Chemotherapy, 24, pp. 812-814, (1983)
  • [34] Meyers B.R., Wilkinson P., Mendelson M.H., Walsh S., Bournazos C., Et al., Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers, Antimicrobial Agents and Chemotherapy, 35, pp. 2098-2101, (1991)
  • [35] Mihindu J.C.L., Scheid W.M., Bolton N.D., Spyker D.A., Swabb E.A., Et al., Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction, Antimicrobial Agents and Chemotherapy, 24, pp. 252-261, (1983)
  • [36] Nakagawa K., Koyama M., Tachibana A., Komiya M., Kikuchi Y., Et al., Pharmacokinetics of cefotetan (YM09330) in humans, Antimicrobial Agents and Chemotherapy, 22, pp. 935-941, (1982)
  • [37] Nilsen O.G., Saltvedt E., Walstad R.A., Marstein S., Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function, American Journal of Medicine, 92, pp. 38S-40S, (1992)
  • [38] Plantier J., Forrey A.W., O'Neill M.A., Blair A.D., Christopher T.G., Et al., Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay, Journal of Infectious Diseases, 134, pp. 5323-5330, (1976)
  • [39] Scheid W.M., Spyker D.A., Donowitz G.R., Bolton W.K., Sande M.A., Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects, Antimicrobial Agents and Chemotherapy, 19, pp. 613-619, (1981)
  • [40] Schentag J.J., Nix D.E., Adelman M.H., Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin, DICP, Annals of Pharmacotherapy, 25, pp. 1050-1057, (1991)